Tarsus Pharmaceuticals, Inc. (TARS): who owns it and who trades it
As of Nov 16, 2026, TARS insiders reported 59 open-market sales worth $20M and no purchases in the last 12 months, with 64% of the sale value made under pre-set 10b5-1 plans. The largest seller was Bobak R. Azamian (CEO), with $5.2M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Tarsus Pharmaceuticals
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns TARS
256 funds and institutions reported TARS shares worth $3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 9.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 3.86M | 8.96% | $243M | +9% |
| Deep Track Capital, LP | 3.67M | 8.52% | $231M | +2% |
| Rtw Investments, LP | 3.36M | 7.80% | $211M | +0% |
| Jupiter Topco LLC | 2.81M | 6.53% | $177M | – |
| Paradigm Biocapital Advisors LP | 2.78M | 6.45% | $175M | +8% |
| Assenagon Asset Management S.A. | 1.89M | 4.40% | $119M | +48% |
| Morgan Stanley | 1.83M | 4.25% | $115M | -6% |
| Vanguard Capital Management LLC | 1.79M | 4.17% | $113M | +2% |
| Jennison Associates LLC | 1.66M | 3.87% | $105M | -3% |
| Tang Capital Management LLC | 1.57M | 3.65% | $98.7M | +32% |
| Millennium Management LLC | 1.43M | 3.32% | $89.8M | +153% |
| Bank of America Corp | 1.19M | 2.77% | $75.1M | -0% |
| Geode Capital Management, LLC | 1.11M | 2.57% | $69.6M | -1% |
| State Street Corp | 1.07M | 2.49% | $67.5M | +10% |
| Vestal Point Capital, LP | 1.05M | 2.44% | $66.1M | +425% |
| Invesco Ltd. | 785,808 | 1.83% | $49.5M | +6% |
| Goldman Sachs Group Inc | 742,693 | 1.73% | $46.7M | +69% |
| Frazier Life Sciences Management, L.P. | 728,644 | 1.69% | $45.9M | No change |
| D. E. Shaw & Co., Inc. | 710,559 | 1.65% | $44.7M | -10% |
| FMR LLC (Fidelity) | 672,949 | 1.56% | $42.4M | -8% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, TARS insiders reported $0 of open-market purchases and $20M of sales. 64% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | William J Phd Link | Director | Sale plan | 66 | $80.01 | $5.3K | Form 4 |
| Sep 15, 2026 | William J Phd Link | Director | Sale plan | 759 | $79.00 | $60K | Form 4 |
| Sep 15, 2026 | William J Phd Link | Director | Sale plan | 11,675 | $78.33 | $915K | Form 4 |
| Sep 4, 2026 | Bobak R. Azamian | CEO | Sale plan | 2,900 | $91.27 | $265K | Form 4 |
| Sep 4, 2026 | Bobak R. Azamian | CEO | Sale plan | 7,100 | $90.27 | $641K | Form 4 |
| Sep 4, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sale plan | 1,590 | $85.00 | $135K | Form 4 |
| Sep 4, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sale plan | 1,590 | $90.00 | $143K | Form 4 |
| Sep 4, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sale plan | 5,387 | $85.00 | $458K | Form 4 |
| Sep 4, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sale plan | 5,386 | $90.00 | $485K | Form 4 |
| Sep 4, 2026 | Seshadri Neervannan | Chief Operating Officer | Sale plan | 4,564 | $85.00 | $388K | Form 4 |
| Sep 2, 2026 | Bobak R. Azamian | CEO | Sale plan | 10,000 | $80.06 | $801K | Form 4 |
| Sep 2, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sale plan | 1,590 | $80.00 | $127K | Form 4 |
| Sep 2, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sale plan | 5,387 | $80.00 | $431K | Form 4 |
| Sep 1, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sale plan | 4,601 | $73.86 | $340K | Form 4 |
| Jun 17, 2026 | Bobak R. Azamian | CEO | Sale plan | 5,418 | $61.81 | $335K | Form 4 |
| Jun 17, 2026 | Bobak R. Azamian | CEO | Sale plan | 4,582 | $61.24 | $281K | Form 4 |
| Jun 16, 2026 | Jeffrey S Farrow | See Remarks | Sale | 14,396 | $60.95 | $877K | Form 4 |
| Jun 15, 2026 | Katherine Goodrich | Director | Sale plan | 2,954 | $62.08 | $183K | Form 4 |
| Jun 15, 2026 | William J Phd Link | Director | Sale plan | 10,572 | $61.97 | $655K | Form 4 |
| Jun 15, 2026 | William J Phd Link | Director | Sale plan | 1,928 | $62.94 | $121K | Form 4 |
| Mar 20, 2026 | Seshadri Neervannan | Chief Operating Officer | Sale plan | 2,989 | $66.75 | $200K | Form 4 |
| Mar 19, 2026 | Dianne C. Whitfield | Chief Human Resources Of | Sale | 4,174 | $67.00 | $280K | Form 4 |
| Mar 19, 2026 | Bryan Wahl | General Counsel | Sale | 4,231 | $67.00 | $283K | Form 4 |
| Mar 19, 2026 | Seshadri Neervannan | Chief Operating Officer | Sale | 4,589 | $67.00 | $307K | Form 4 |
| Mar 19, 2026 | Aziz Mottiwala | Chief Commercial Officer | Sale | 4,440 | $67.00 | $297K | Form 4 |
| Mar 19, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sale | 390 | $67.00 | $26.1K | Form 4 |
| Mar 19, 2026 | Jeffrey S Farrow | See Remarks | Sale | 2,186 | $67.00 | $146K | Form 4 |
| Mar 19, 2026 | Bobak R. Azamian | CEO | Sale | 11,964 | $67.00 | $802K | Form 4 |
| Mar 18, 2026 | Dianne C. Whitfield | Chief Human Resources Of | Sale | 4,071 | $68.71 | $280K | Form 4 |
| Mar 18, 2026 | Bryan Wahl | General Counsel | Sale | 4,125 | $68.71 | $283K | Form 4 |
| Mar 18, 2026 | Seshadri Neervannan | Chief Operating Officer | Sale | 3,610 | $68.71 | $248K | Form 4 |
| Mar 18, 2026 | Aziz Mottiwala | Chief Commercial Officer | Sale | 4,330 | $68.71 | $298K | Form 4 |
| Mar 18, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sale | 379 | $68.71 | $26K | Form 4 |
| Mar 18, 2026 | Jeffrey S Farrow | See Remarks | Sale | 2,133 | $68.71 | $147K | Form 4 |
| Mar 18, 2026 | Bobak R. Azamian | CEO | Sale | 11,667 | $68.71 | $802K | Form 4 |
| Mar 17, 2026 | Dianne C. Whitfield | Chief Human Resources Of | Sale | 4,029 | $69.42 | $280K | Form 4 |
| Mar 17, 2026 | Bryan Wahl | General Counsel | Sale | 4,084 | $69.42 | $284K | Form 4 |
| Mar 17, 2026 | Seshadri Neervannan | Chief Operating Officer | Sale | 3,125 | $69.42 | $217K | Form 4 |
| Mar 17, 2026 | Aziz Mottiwala | Chief Commercial Officer | Sale | 4,286 | $69.42 | $298K | Form 4 |
| Mar 17, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sale | 375 | $69.42 | $26K | Form 4 |
| Mar 17, 2026 | Jeffrey S Farrow | See Remarks | Sale | 2,111 | $69.42 | $147K | Form 4 |
| Mar 17, 2026 | Bobak R. Azamian | CEO | Sale | 10,972 | $69.42 | $762K | Form 4 |
| Mar 16, 2026 | William J Phd Link | Director | Sale plan | 8,378 | $69.03 | $578K | Form 4 |
| Mar 16, 2026 | William J Phd Link | Director | Sale plan | 493 | $69.75 | $34.4K | Form 4 |
| Mar 16, 2026 | William J Phd Link | Director | Sale plan | 3,629 | $68.09 | $247K | Form 4 |
| Mar 4, 2026 | Seshadri Neervannan | Chief Operating Officer | Sale plan | 8,366 | $76.67 | $641K | Form 4 |
| Jan 2, 2026 | Dianne C. Whitfield | Chief Human Resources Of | Sale plan | 835 | $81.90 | $68.4K | Form 4 |
| Jan 2, 2026 | Dianne C. Whitfield | Chief Human Resources Of | Sale plan | 893 | $82.93 | $74.1K | Form 4 |
| Jan 2, 2026 | Dianne C. Whitfield | Chief Human Resources Of | Sale plan | 8,122 | $80.71 | $656K | Form 4 |
| Jan 2, 2026 | Dianne C. Whitfield | Chief Human Resources Of | Sale plan | 5,715 | $80.09 | $458K | Form 4 |
| Dec 24, 2025 | Bobak R. Azamian | CEO | Sale plan | 5,443 | $82.41 | $449K | Form 4 |
| Dec 24, 2025 | Bobak R. Azamian | CEO | Sale plan | 557 | $83.54 | $46.5K | Form 4 |
| Dec 16, 2025 | Dianne C. Whitfield | Chief Human Resources Of | Sale plan | 7,397 | $80.10 | $592K | Form 4 |
| Dec 16, 2025 | Elizabeth Yeu Lin | Chief Medical Officer | Sale | 2,078 | $79.50 | $165K | Form 4 |
| Dec 15, 2025 | William J Phd Link | Director | Sale plan | 5,046 | $80.80 | $408K | Form 4 |
| Dec 15, 2025 | William J Phd Link | Director | Sale plan | 1,148 | $82.39 | $94.6K | Form 4 |
| Dec 15, 2025 | William J Phd Link | Director | Sale plan | 5,680 | $80.71 | $458K | Form 4 |
| Dec 15, 2025 | William J Phd Link | Director | Sale plan | 4,766 | $81.50 | $388K | Form 4 |
| Dec 15, 2025 | William J Phd Link | Director | Sale plan | 6,306 | $81.75 | $516K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Bobak R. Azamian | President/CEO and Board Chair, Director | – | $5.2M | Sep 4, 2026 |
| William J Phd Link | Director | – | $4.5M | Sep 15, 2026 |
| Dianne C. Whitfield | Chief Human Resources Officer | – | $2.7M | Mar 19, 2026 |
| Elizabeth Yeu Lin | Chief Medical Officer | – | $2.4M | Sep 4, 2026 |
| Seshadri Neervannan | Chief Operating Officer | – | $2M | Sep 4, 2026 |
| Jeffrey S Farrow | See Remarks | – | $1.3M | Jun 16, 2026 |
| Aziz Mottiwala | Chief Commercial Officer | – | $893K | Mar 19, 2026 |
| Bryan Wahl | General Counsel | – | $850K | Mar 19, 2026 |
| Katherine Goodrich | Director | – | $183K | Jun 15, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TARS short interest
High short interest. 12.3% of TARS shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 24%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 6.07M TARS shares were sold short, 12.3% of the shares outstanding, up 5.8% from the report before. At the average daily volume of 874,486 shares, buying them all back would take about 6.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 6.07M | 12.30% | +6% | 874,486 | 6.9 |
| Oct 15, 2026 | 5.73M | 13.06% | -6% | 1.00M | 5.7 |
| Sep 30, 2026 | 6.07M | 13.83% | -1% | 732,012 | 8.3 |
| Sep 15, 2026 | 6.13M | 13.96% | +2% | 923,426 | 6.6 |
| Aug 31, 2026 | 6.01M | 13.70% | +0% | 613,155 | 9.8 |
| Aug 14, 2026 | 6.00M | 13.67% | -0% | 801,093 | 7.5 |
| Jul 31, 2026 | 6.02M | 13.71% | +4% | 914,420 | 6.6 |
| Jul 15, 2026 | 5.78M | 13.44% | -2% | 1.82M | 3.2 |
| Jun 30, 2026 | 5.89M | 13.69% | +18% | 943,186 | 6.2 |
| Jun 15, 2026 | 4.98M | 11.57% | -3% | 559,334 | 8.9 |
| May 29, 2026 | 5.13M | 11.91% | +4% | 690,081 | 7.4 |
| May 15, 2026 | 4.91M | 11.40% | +2% | 855,835 | 5.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Tarsus Pharmaceuticals company events
Tarsus Pharmaceuticals filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 3, 2026.
- Nov 3, 2026ResultsReleased financial results. Filing
- Sep 10, 2026DealTarsus Pharmaceuticals, Inc. completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a Delaware corporation, pursuant to that certain Agreement and Plan of Merger, dated as of July 31, 2026, by and among the Company, Alkeus, Apex 2026 Merger Sub, Inc., a Delaware corporation… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Aug 6, 2026AgreementTarsus Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with a syndicate of existing and new healthcare investors for a private placement of: (i) 2,098,519 shares of common stock, par value $0.0001 per share, of the Company, at a purchase price of $56.00 per share; and (ii)… Filing
- Aug 6, 2026AgreementTarsus Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger with Alkeus Pharmaceuticals, Inc., a Delaware corporation, Apex 2026 Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, and Shareholder Representative Services LLC, as the securityholders’… Filing
- Jul 13, 2026LeadershipTarsus Pharmaceuticals, Inc. announced that Aziz Mottiwala would be leaving his role as the Company’s Chief Commercial Officer and leaving his employment with the Company on July 15, 2026, to pursue a new opportunity as Chief Executive Officer of a public medical device company. Filing
- Jul 8, 2026AgreementTarsus Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger with iRenix Medical, Inc., a Delaware corporation, Dolores Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company and Fortis Advisors LLC, as the securityholders’ representative. Filing
- Jun 29, 2026VoteReported shareholder vote results. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Feb 23, 2026ResultsReleased financial results. Filing
- Feb 18, 2026LeadershipThe Board of Directors of Tarsus Pharmaceuticals, Inc., upon the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Board from seven to eight directors and appointed David E.I. Pyott to the Board, effective immediately. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Tarsus Pharmaceuticals financials
Famous investors that hold TARS
4 of the 50 well-known investors we track reported holding TARS in their latest 13F filing. The largest position is Israel Englander's, worth $85.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 1.09M | $85.5M | 0.1% | -23% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 109,170 | $8.2M | 0.0% | -55% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 85,000 | $6.7M | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 72,100 | $5.7M | 0.0% | +675% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named TARS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Paradigm BioCapital Advisors LP | 13G/A | 4.7% |
| Nov 16, 2026 | Paradigm BioCapital Advisors LP | 13G/A | 4.7% |
| Nov 5, 2026 | FMR LLC | 13G | 6.4% |
| Nov 5, 2026 | FMR LLC | 13G | 6.4% |
Questions about Tarsus Pharmaceuticals, Inc. (TARS) stock
Who owns the most TARS stock?
The largest reported owner of Tarsus Pharmaceuticals, Inc. (TARS) is BlackRock, Inc., with 9.0% of the company. In total, 256 funds and institutions reported holding TARS at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are TARS insiders buying or selling?
In the last 12 months, TARS insiders reported no open-market purchases and 59 sales worth $20M. The latest trade was on Sep 15, 2026. See every trade.
What is the short interest in TARS?
As of Oct 30, 2026, 6.07M TARS shares were sold short, 12.3% of the shares outstanding, up 5.8% from the report before. At the average daily volume of 874,486 shares, buying them all back would take about 6.9 trading days (days to cover). See the history.
Which famous investors hold TARS?
4 of the 50 well-known investors we track reported TARS in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $85.5M. See all holders.
Executive pay
Tarsus Pharmaceuticals's chief executive was paid a total of $6.6M for the year ended Dec 31, 2025, down 16% from $7.9M the year before. In the last 12 months, Tarsus Pharmaceuticals's executives and directors bought no stock on the open market and sold $20M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.